Clinical Trial Update: Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating a CBD/CBG/THC combination as adjuvant therapy for chronic migraine and related headaches was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Headache
• Medication-overuse Headache
• Migraine

Drugs mentioned

• Cannabidiol 133 mg + Cannabigerol 66 mg + Tetrahydrocannabinol 4 mg (Cannabidiol + Cannabigerol + Tetrahydrocannabinol)

Snippet

Sponsor: Hospital Israelita Albert Einstein | Conditions: Chronic Migraine, Headache, Overuse Headache Medication | Phase 2, Phase 3 | Status: TERMINATED